Major lupus organ involvement: severe lupus nephritis

被引:21
作者
Avihingsanon, Y. [1 ]
Hirankarn, N. [2 ]
机构
[1] Chulalongkorn Univ, Fac Med, Div Renal, Dept Med,Lupus Res Unit, Bangkok 10330, Thailand
[2] Chulalongkorn Univ, Fac Med, Dept Microbiol, Bangkok 10330, Thailand
关键词
Asia; genetic; immunosuppressive therapy; lupus nephritis; SYSTEMIC-LUPUS; LONG-TERM; MYCOPHENOLATE-MOFETIL; CONTROLLED-TRIAL; INTRAVENOUS CYCLOPHOSPHAMIDE; CLINICOPATHOLOGICAL FINDINGS; PULSE METHYLPREDNISOLONE; GROWTH-FACTOR; SAUDI-ARABIA; ERYTHEMATOSUS;
D O I
10.1177/0961203310376522
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lupus nephritis is a common and severe complication of systemic lupus erythematosus. A number of patients have nephritis as a presenting feature that, in its severe form, can shortly lead to end-stage renal disease and/or death. Renal flare usually occurs a few years after the first episode and is remarkably predominant in the Asian population. Frequent monitoring for renal flare enhances early recognition and timely treatment. The mainstay therapy continues to be the prolonged use of cytotoxic/immunosuppressive drugs that have a number of undesirable effects, particularly ovarian failure and development of opportunistic infections. This review will focus on the pathogenesis and the unique genetic factors found in Asian patients with lupus nephritis. Here, we propose an appropriate management scheme for the treatment of lupus nephritis in Asian patients. Lupus (2010) 19, 1391-1398.
引用
收藏
页码:1391 / 1398
页数:8
相关论文
共 58 条
[1]   Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia [J].
Al Arfaj, A. S. ;
Khalil, N. .
LUPUS, 2009, 18 (05) :465-473
[2]   Viral 5′-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses [J].
Allam, Ramanjaneyulu ;
Pawar, Rahul D. ;
Kulkarni, Onkar P. ;
Hornung, Veit ;
Hartman, Gunter ;
Segerer, Stephan ;
Akira, Shizuo ;
Endres, Stefan ;
Anders, Hans-Joachim .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (12) :3487-3498
[3]  
ANTHONY C, 2000, IMMUNOPHARMACOLOGY, V47, P85
[4]   LONG-TERM FOLLOW-UP OF PATIENTS WITH LUPUS NEPHRITIS - A STUDY BASED ON THE CLASSIFICATION OF THE WORLD-HEALTH-ORGANIZATION [J].
APPEL, GB ;
COHEN, DJ ;
PIRANI, CL ;
MELTZER, JI ;
ESTES, D .
AMERICAN JOURNAL OF MEDICINE, 1987, 83 (05) :877-885
[5]   Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].
Appel, Gerald B. ;
Contreras, Gabriel ;
Dooley, Mary Anne ;
Ginzler, Ellen M. ;
Isenberg, David ;
Jayne, David ;
Li, Lei-Shi ;
Mysler, Eduardo ;
Sanchez-Guerrero, Jorge ;
Solomons, Neil ;
Wofsy, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112
[6]   PREDICTING RENAL OUTCOMES IN SEVERE LUPUS NEPHRITIS - CONTRIBUTIONS OF CLINICAL AND HISTOLOGIC DATA [J].
AUSTIN, HA ;
BOUMPAS, DT ;
VAUGHAN, EM ;
BALOW, JE .
KIDNEY INTERNATIONAL, 1994, 45 (02) :544-550
[7]  
Austin HA, 1999, SEMIN NEPHROL, V19, P2
[8]   Clinical evaluation and monitoring of lupus kidney disease [J].
Austin, HA .
LUPUS, 1998, 7 (09) :618-621
[9]   THERAPY OF LUPUS NEPHRITIS - CONTROLLED TRIAL OF PREDNISONE AND CYTOTOXIC DRUGS [J].
AUSTIN, HA ;
KLIPPEL, JH ;
BALOW, JE ;
LERICHE, NGH ;
STEINBERG, AD ;
PLOTZ, PH ;
DECKER, JL .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 314 (10) :614-619
[10]  
Austin HA, 1996, SEMIN NEPHROL, V16, P527